New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
- Written by PR Newswire
![]() |
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types
SEOUL, South Korea, Feb. 16, 2024 /PRNewswire/ -- Lunit...















